IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2815
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$145M
J. Scott Wolchko
Fate Therapeutics, Inc. develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cells product candidates.
Headcount
550
HQ Base
San Diego, California
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$FATE FATE THERAPEUTICS INC | 45 | 35 | 34 | 48 | - | - | -64.8% | -44.1% | 100.0% | -2042.9% | -1874.9% | -74.3% | 0.0% | 47.0x | $145M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
FATE THERAPEUTICS INC (FATE) receives a "Reduce" rating with a composite score of 44.9/100. It ranks #2815 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
No analyst ratings for FATE.
View All RatingsVerified SEC Filings Aggregate • FATE
Direct unfiltered access to 10-K, 10-Q and 8-K filings for FATE.
Open Regulatory DossierFigures adjusted for stock splits and restatements where applicable.
TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.
YOY expansion rate
Core pricing power
Operating efficiency
Equity efficiency
Financial leverage
Direct cash return
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
ROIC -81.0% vs WACC 8.0% (spread -89.0%)
GM 100% vs sector 44%, OM -2043% vs sector 3%
Capital turnover 0.05x, R&D intensity 1561.6%
Rev growth -74%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate FATE THERAPEUTICS INC (FATE) as a Reduce with a composite score of 44.9/100 at a current price of $1.63. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
FATE THERAPEUTICS INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 44.9/100 places it at rank #2815 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 100% signal strong pricing power.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
FATE THERAPEUTICS INC represents a reduce based on multi-factor quantitative performance.
FATE THERAPEUTICS INC receives a Reduce rating from our analysis, with a composite score of 44.9/100 and 2 out of 5 stars, ranking #2815 out of 7,333 stocks. FATE's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
FATE's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -64.8% (sector avg: -1.9%), gross margins of 100.0% (sector avg: 44.1%), net margins of -1874.9% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 34/100, FATE appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 0.72x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
FATE THERAPEUTICS INC's investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -74.3% vs. a sector average of 6.7% and a return on assets of -44.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
FATE is currently showing below-average momentum at 48/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -74.3% year-over-year, while a beta of 0.81 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
FATE's stability score of 42/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.81 and a debt-to-equity ratio of 47.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
FATE THERAPEUTICS INC's short interest score of 38/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 47.00x), micro-cap liquidity risk. At $145M (micro-cap), FATE carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
FATE THERAPEUTICS INC is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2815 of 7,333 overall (62nd percentile). Key comparisons include ROE of -64.8% trailing the -1.9% sector median and operating margins of -2042.9% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While FATE currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (34) would have the largest impact on the composite score.
ROE 3309% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 127% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 81490% BELOW SECTOR MEDIAN
Relative to Manufacturing Median (N=1906)
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.
Lower quality and stability scores may indicate governance concerns. Verified against factor-based integrity benchmarks.
No recent insider transactions available for FATE
Institutional cap table data requires verified 13F filing feeds.
Access SEC 13F Dossier →Insider transaction data currently awaiting regulatory verification.
Access SEC Form 4 Dossier →Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Above 50MA
37.18%
Net New Highs
+51081
Key Insights Significantly high institutional ownership implies Fate Therapeutics' stock price is sensitive to their...
Harmony Biosciences Holdings, Inc. (HRMY) reported better-than-expected earnings and revenue for the second quarter of 2024. However, the company's stock has underperformed the market so far this year, and the earnings outlook is unfavorable, leading to a Zacks Rank #5 (Strong Sell) rating.
Author Dan Mulvagh returns to the literary scene with the release of "Ballot: When Fate Called Their Name" (published by Xlibris NZ), a thought-provoking novel that sheds light on the personal struggles of a generation caught between opposing political and philosophical worldviews.
The announcement of the closure of FATE, the only tire manufacturer entirely owned by the Argentine capital and with more than 80 years of history, became the most visible symbol of the fracture facing industry under the government of Javier Milei.